Skip to content
Screener

Retained Earnings at other companies

Pfizer logo
PfizerPFE
$117.24B-2.0%
Amgen logo
AmgenAMGN
-$22.28B+13.4%
Incyte logo
IncyteINCY
$1.1B+316%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$648.67M-19.8%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$2.17B-15.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$1.7B-37.0%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$7.14B+366%
Enterprise value$6.92B+372%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:21 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-205170
Line itemMarch 31, 2026December 31, 2025
Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 39,414 and 67,414 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively29,19053,830
Series B non-voting convertible preferred stock, $0.001 par value; 20,580 shares authorized; 4,516 shares issued and outstanding at March 31, 2026 and December 31, 202535,56335,563
Common stock, $0.001 par value; 300,000,000 shares authorized; 170,773,803 and 160,980,024 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively171161
Additional paid-in capital1,828,9561,734,882
Accumulated other comprehensive income (loss)(415)355
Accumulated deficit(1,285,772)(1,188,420)
Total stockholders’ equity607,693636,371
Total liabilities and stockholders’ equity$903,006$937,607

Item 1. Financial Statements (Unaudited)

FAQ

What is Cogent Biosciences, Inc.'s retained earnings?
Cogent Biosciences, Inc. (COGT) reported retained earnings of -$1.29B in Q1 2026.
How has Cogent Biosciences, Inc.'s retained earnings changed year-over-year?
Cogent Biosciences, Inc.'s retained earnings decreased by 38.0% year-over-year, from -$931.47M to -$1.29B.
What is the long-term trend for Cogent Biosciences, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s retained earnings has grown at a 43.0% compound annual growth rate (CAGR), from -$198.7M to -$1.19B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Cogent Biosciences, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude